Option chain shows key data for Greenwich LifeSciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Greenwich LifeSciences.

Greenwich LifeSciences (NASDAQ:GLSI) Stock, Option Chain

Greenwich LifeSciences

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.

Wall Street US stocks

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

EVBN

GLSI

UBFO

Over $1M Bet On United Security Bancshares? Check Out These 3 Stocks Insiders Are Buying

Small Cap

HROW

Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades.

Insiders Buying Greenwich LifeSciences And 2 Other Stocks

man-2425121

Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01.

Why Greenwich Lifesciences (GLSI) Stock Is Skyrocketing

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences Inc

Press Releases

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI)

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Alector

C4 Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Elicio Therapeutics

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

TuHURA Biosciences

Inventiva S.A. - American Depository Shares

Inventiva

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Kodiak Sciences

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Lyell Immunopharma

Seres Therapeutics

Nkarta

Puma Biotechnology

RAPT Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Instil Bio

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tango Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Zentalis Pharmaceuticals, Inc. - common stock

Comments

Greenwich LifeSciences

Greenwich LifeSciences (GLSI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga